XenoPort, Inc. - XNPT - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: May 19, 2013

XenoPort, Inc. - SIC # 2834

Ticker	Exchange	SIC #	Website	Latest Ticker
XNPT	Nasdaq	2834	http://www.xenoport.com/	5.5401 -0.1799
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for XenoPort, Inc. XenoPort weakness creates buying opportunity, says Wells Fargo - May 21st, 2013 5:53 am Nasdaq stocks posting largest percentage decreases - May 20th, 2013 4:06 pm Nasdaq stocks posting largest percentage decreases - May 20th, 2013 4:06 pm XenoPort's CEO Presents at Special Conference (Transcript) - May 20th, 2013 12:26 pm Why XenoPort Shares Stumbled - May 20th, 2013 11:25 am XenoPort to drop multiple sclerosis drug, shares fall - May 20th, 2013 10:25 am XenoPort MS treatment fails in late-stage testing - May 20th, 2013 10:02 am XenoPort MS treatment fails in late-stage testing - May 20th, 2013 10:02 am XenoPort Sinks as Spasticity Drug For MS Fails in Trial - May 20th, 2013 9:00 am Websense rockets on $1 billion LBO - May 20th, 2013 6:32 am XenoPort to drop multiple sclerosis drug after trial failure - May 20th, 2013 4:42 am InPlay: Xenoport reports top-line results of Phase 3 trial of arbaclofen placarbil for spasticity in multiple sclerosis patients; trial was unsuccessful in demonstrating that AP provided statistically significant improvement relative to pla - May 20th, 2013 4:31 am XenoPort Reports Top-Line Results of Phase 3 Trial of Arbaclofen Placarbil for Spasticity in Multiple Sclerosis Patients - May 20th, 2013 4:30 am XenoPort: Horizant likely available in early June - May 17th, 2013 8:53 am XenoPort: Horizant likely available in early June - May 17th, 2013 8:53 am XenoPort Provides Update on Availability of Horizant - May 17th, 2013 6:30 am XENOPORT INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders - May 15th, 2013 3:56 am XENOPORT INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibit - May 6th, 2013 7:17 am XenoPort Announces New Employment Inducement Awards - May 3rd, 2013 2:30 pm Biotech Stock Value Fundamentally Based on Individual Drug Development and the Competing Landscape: Expert Analyst Boris Peaker Discusses His Coverage of the Biotechnology Sector with The Wall Street Transcript - May 1st, 2013 9:29 am View All Current Headlines >>